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Summary 
Consolidation with high dose chemotherapy and autologous stem cell transplantation (ASCT) is the 
standard of care for transplant eligible patients with multiple myeloma, based on randomised trials 
showing improved progression free survival with autologous transplantation following combination 
chemotherapy induction. These trials were performed before novel agents were introduced, and 
subsequently combinations of immunomodulatory drugs (IMiDs) and proteasome inhibitors as 
induction therapy have significantly improved rates and depth of response. Ongoing randomised trials 
are testing whether conventional autologous transplantation continues to improve responses following 
novel agent induction. While these results are awaited, it is important to review strategies for 
improving outcomes following ASCT.  Conditioning prior to ASCT with higher doses of melphalan, 
and combinations of melphalan with other agents, including radiopharmaceuticals have been 
explored. Tandem ASCT, consolidation and maintenance therapy following ASCT have been 
investigated in phase III trials. Experimental cellular therapies using ex vivo primed dendritic cells , ex 
vivo expanded autologous lymphocytes, KIR-mismatched allogeneic NK cells, and genetically 
modified T cells are also in phase I trials to augment ASCT. This review summarises these strategies 
and highlights the importance of exploring strategies to augment ASCT even in the era of novel agent 
induction. 
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Introduction 
Myeloma represents just over 1% of all cancers, and despite a recent increase in available 
therapeutics, the disease remains incurable with estimated 5 year survival just over 50% (Pulte et al, 
2015). Randomised controlled trial (RCT) evidence from France and the UK demonstrated improved 
disease response and overall survival following autologous haematopoietic stem cell transplantation 
(ASCT), compared with conventional chemotherapy (Attal et al, 1996; Child et al, 2003). However, 
subsequent trials from France, the USA and Spain did not show an overall survival benefit, although 
Fermand et al. did show an improvement in progression free survival (Bladé et al, 2005; Fermand et 
al, 2005a; Barlogie et al, 2006a). The differences in outcomes between groups may be accounted for, 
by prolonged use of conventional chemotherapy in the study by Fermand et al, and a high rate of 
ASCT salvage therapy at relapse in that by Barlogie et al.  A Dutch trial demonstrated that after 
treatment with intermediate dose melphalan, further treatment with ASCT did not improve outcomes 
(Sonneveld et al, 2007). These trials support the use of high dose alkylating agents in myeloma 
treatment. For patients who are fit for high dose therapy (approximately one third of newly diagnosed 
patients), treatment with chemotherapy conditioning followed by ASCT has been the standard of care, 
and the standard conditioning regimen has been a single dose of intravenous melphalan at 200mg/m2 
(Moreau et al, 2002). There has been much interest in augmenting conditioning but no regimen has 
been shown to improve outcomes in a randomised trial.  Adjunctive strategies have also been 
explored: second tandem ASCT; consolidation and maintenance chemotherapy; attempts to augment 
immune responses post transplant; and new drugs, particularly monoclonal antibodies. This review 
will evaluate the strategies employed and make recommendations for further research in this area. 
Methods 
We searched Pubmed using the terms myeloma, autograft, asct, autologous, transplant, graft, 
transplantation, conditioning, preparative regimen, treatment, RCT, randomised, trial, and induction in 
various permutations, yielding 1393 results, and abstracts from the American Society of Haematology 
(ASH) and American Society of Clinical Oncology (ASCO) Annual meetings. Reference lists from 
these search results were used to identify other relevant publications. In the tables, overall response 
rate (ORR) is the proportion of patients achieving a partial response (>50% reduction in paraprotein) 
or better. 
Novel agent induction 
Induction for transplant eligible patients with immunomodulatory drugs (thalidomide and 
lenalidomide) and proteasome inhibitors (bortezomib) has improved response rates prior to ASCT. 
The HOVON50 trial demonstrated that substituting thalidomide for vincristine in the VAD regimen 
(vincristine, doxorubicin and dexamethasone) could increase pre-ASCT overall response rates (ORR) 
from 54% to 72% (Lokhorst et al, 2008). The benefit conferred by thalidomide combinations in 
induction was confirmed by the Myeloma IX and Total Therapy 2 trials (Morgan et al, 2012; Barlogie 
et al, 2006b). The IFM 2005-01 trial demonstrated that bortezomib and dexamethasone was also 
superior to VAD, increasing the pre-ASCT response rate to 79% from 63%, (Harousseau et al, 2010), 
and a similar improvement with bortezomib-based induction was observed in the 
HOVON65/GMMGHD4 trial (Sonneveld et al, 2012).  Cavo et al tested the addition of bortezomib to 
thalidomide plus dexamethasone, and this combination of both IMiD and proteasome inhibitor 
significantly improved both pre-ASCT ORR (93% vs. 79%) and progression-free survival (PFS) 
(Cavo et al, 2010). Combining lenalidomide with bortezomib plus dexamethasone produced an ORR 
of 94% in a phase II IFM study (Roussel et al, 2014). An ongoing phase II study of carfilzomib, 
lenalidomide and dexamethasone for both induction and maintenance obtained an ORR pre-ASCT of 
98% and demonstrated no unexpected toxicity (Zimmerman et al, 2015). 
The improvement in responses seen with newer induction programs has prompted further trials 
following induction comparing upfront ASCT with a non-transplant option of novel agent 
consolidation followed by maintenance. Recently published phase III trials comparing ASCT with 
lenalidomide-containing regimens found ASCT confers superior PFS, although at a median follow up 
of 52 months no differences in overall survival were observed (Palumbo et al, 2014a; Gay et al, 
2015). An ongoing French/American RCT (the IFM/DFCI  2009 study) compares ASCT plus 2 cycles 
of VRD with 5 cycles of VRD alone, and results from the French cohort show superior complete 
response (CR) rate (58% vs 46%) and 3-year PFS (61% vs 48%) in the ASCT arm (Attal et al, 2015).  
EMN02/HO95 is a European 2x2 factorial RCT, currently recruiting patients to compare ASCT 
versus bortezomib, melphalan and prednisolone (VMP) intensification, and then consolidation with 
bortezomib, lenalidomide and dexamethasone (VRD) versus no consolidation (Sonneveld et al, 2014). 
The possible merits of a delayed transplant strategy are being evaluated in the PADIMAC phase II 
study for patients achieving very good partial response (VGPR) or CR after bortezomib, doxorubicin 
and dexamethasone (PAD): up to 20% of patients had negative minimal residual disease (MRD) post 
induction, and survival outcomes are awaited (Popat et al, 2014).  
Conditioning for ASCT 
High dose melphalan 200mg/m2 (mel200) delivered as a single dose for conditioning has been shown 
in a randomised trial to be less toxic and at least as effective as melphalan 140mg/m2 (mel140) plus 
8Gy total body irradiation (TBI) (Moreau et al, 2002), and mel200 has since remained the gold 
standard for single ASCT in patients with normal renal function. Escalating the dose of melphalan 
above 200mg/m2 is prohibitively toxic to the gastrointestinal tract. Minimising oral mucositis with 
protective agents amifostine (Spencer et al, 2005) and palifermin, a keratinocyte growth factor, may 
facilitate dose increases to 280mg/m2 for a proportion of patients (Abidi et al, 2013). However wide 
variability in melphalan exposure due to pharmacokinetic differences has been reported. In a 
pharmacokinetic study of high dose melphalan in 100 patients, higher mucositis rates and improved 
disease response were seen in patients with higher exposure to melphalan, as measured by increased 
area under the curve of both total and unbound melphalan (Nath et al, 2010).  
Melphalan and chemotherapeutic agent combinations 
A number of chemotherapeutic agents and combinations with Mel200 have been tested in clinical 
studies, but the majority of these studies enrolled fewer than 100 patients and were non randomised 
studies, so it is difficult to draw significant conclusions (Table I). 
Regarding alkylating agents in combination with melphalan: oral busulfan is demonstrably too toxic, 
as  8% of patients in a Spanish study developed veno-occlusive disease, with a case fatality rate of 
25% (Lahuerta et al, 2010). The intravenous busulfan formulation introduced in 2003 reduces hepatic 
exposure via the portal circulation, and a non-randomized study (n=153) comparing mel140 plus 
busulfan 9.6mg/kg i.v. with mel200 suggested a small benefit in terms of progression-free survival but 
increased treatment-related mortality, with neither difference reaching statistical significance (Blanes 
et al, 2013). Adding cyclophosphamide 120mg/kg to mel200 worsens outcomes (Desikan et al, 2000), 
and further addition of idarubicin progressively increases treatment-related mortality to 20% (Fenk et 
al, 2005).  An RCT of cyclophosphamide, oral busulfan and total marrow irradiation versus two 
consecutive ASCT with mel200 found the chemoradiotherapy regimen to be more toxic with no 
significant improvement in efficacy (Knop et al, 2007). Reports from MD Anderson Cancer Centre 
using mel140 plus topotecan and cyclophosphamide in combination show outcomes comparable to 
mel200 but a controlled comparison is required (Donato et al, 2004; Kazmi et al, 2011). The addition 
of carmustine to mel200 in single arm studies was found to be safe, with comparable PFS and OS to 
previously published Mel200 studies (Comenzo et al, 2006; Chen et al, 2012). More recently 
bendamustine, which has shown single agent activity in relapsed myeloma, was combined with 
Mel200 at escalated doses reaching 225mg/m2 with only one dose-limiting toxicity in the first 100 
days post-transplant. (Mark et al, 2013) 
Melflufen is a dipeptide pro-drug of melphalan, which by virtue of increased intracellular hydrolysis 
is concentrated in myeloma cells. Melflufen induces apoptosis in melphalan-resistant cells and is 
highly effective in mouse models (Chauhan et al, 2013). A phase I/II trial of melflufen and 
dexamethasone in relapsed-refractory myeloma is ongoing, but initial results are encouraging with an 
ORR of 60% (Magarotto et al, 2015). Based on these encouraging results, melflufen as a conditioning 
regimen prior to ASCT should be explored in future trials.   
Topoisomerase inhibitors (doxorubicin, idarubicin, mitoxantrone, topotecan) have been tested in 
combination with melphalan as conditioning, although in vitro data on the combination is limited. The 
addition of cyclophosphamide and idarubicin to mel200 was shown in an RCT to markedly increase 
treatment related mortality (Fenk et al, 2005), but adding cyclophosphamide and topotecan to mel140 
produced promising outcomes in an uncontrolled series (Kazmi et al, 2011). Two small phase II 
studies of mitoxantrone combined with melphalan (combined n=55) suggest outcomes comparable to 
mel200 (Ballestrero et al, 2002; Beaven et al, 2011). 
Arsenic trioxide with ascorbic acid has been explored in a randomised trial recruiting 48 patients, 
combined with mel200. There was no difference in response rate or survival, but no additional 
toxicity was noted (Qazilbash et al, 2008). 
Melphalan with Proteasome Inhibitors and IMiDS 
Synergistic myeloma cell kill in vitro has been noted with the combination of melphalan and 
bortezomib (Ma et al, 2003; Mitsiades et al, 2003). Bortezomib, by inhibiting the proteasome, 
interferes with DNA repair pathways and inhibitors of apoptosis, thus sensitising cells to DNA-
damaging agents such as melphalan. There are currently no randomised data for the addition of 
bortezomib to ASCT conditioning. A French non-randomised phase II study found that adding 
bortezomib 1mg/m2 to mel200 improved complete response (CR) rates from 11% to 35% (Roussel et 
al, 2010), but in contrast two other small studies (combined n=27) using non-randomized control 
patients observed no difference in response rate, though reassuringly no increase in toxicity was 
observed (Huang et al, 2012; Miyamoto et al, 2013). A phase I study suggests that bortezomib is 
more effective when given after melphalan dosing, rather than before, with an increase in CR rates 
from 11% to 30% (Lonial et al, 2010).  In an uncontrolled series, 36% of patients with primary 
refractory myeloma obtained a CR after tandem ASCT with bortezomib given after melphalan 
(Nishihori et al, 2012). Lenalidomide at higher than licensed doses has been combined with mel200 in 
a phase I study of relapsed/refractory myeloma and no lenalidomide related dose-limiting toxicities 
were observed, with 8 of 21 patients (38%) achieving ≥CR (Forsberg et al, 2015). Carfilzomib is a 
recently licensed irreversible proteasome inhibitor, which has been studied in phase III trials in 
relapsed/refractory myeloma (Stewart et al, 2015); a phase I/II trial is currently underway in 
combination with melphalan as a conditioning regimen (CARAMEL trial, NCT01842308). 
Augmentation with radiotherapy/radiopharmaceuticals 
Total body irradiation displays excessive toxicity in trials, but targeted radiotherapy shows promising 
early results. Phase I/II trials of radiophosphonates (containing  153Sm or 166Ho, respectively) added to 
mel200 conditioning showed no change in outcomes with little toxicity, though renal failure due to 
thrombotic microangiopathy was seen with doses >30Gy of the 166Holmium conjugate (Giralt et al, 
2003; Dispenzieri et al, 2010). The combination of bortezomib with the 153Samarium conjugate 
demonstrated promising synergy in mice and merits further clinical investigation (Goel et al, 2006). 
CD66 is expressed on myeloma cells as well as the myeloid lineage: an anti-CD66 radioconjugate 
monoclonal antibody is selective for bone marrow, and appears to be safe in a phase I trial (Orchard et 
al, 2005), with results from the phase II trial awaited. Radio-conjugated CD20 antibodies show 
additional toxicity in phase I when added to mel200 for conditioning (90Y-ibritumomab) (Dispenzieri 
et al, 2011), and limited efficacy when used as a single agent (131I-tositumomab), which may relate to 
low CD20 expression on myeloma cells, with higher response rates correlating with expression of 
CD20 (Lebovic et al, 2012). Radioconjugate antibodies against CD38 and CD138 have been studied 
in animal models, but clinical trials are awaited (Green et al, 2013; Chérel et al, 2013). Tomotherapy 
(radiotherapy delivered from many emitters arranged radially to focus treatment, analogous to 
computed tomography scans) has hitherto only been studied in leukaemias and lymphomas (Pica et al, 
2011), but studies in myeloma are underway. This would require a head-to-head comparison with 
molecularly targeted radiotherapy in future.  
Tandem transplants 
Two consecutive cycles of high dose chemotherapy, with each cycle followed by haematopoietic stem 
cell transplantation/rescue (tandem ASCT), has been extensively investigated by both European and 
US cooperative groups, in an attempt to improve responses (Table II). The Arkansas group have 
undertaken a series of Total Therapy Trials using intensive treatment including tandem ASCT, which 
have achieved impressive results, for instance 41% CR and median OS of 68 months in Total Therapy 
1 (Barlogie et al, 2006c; Barlogie et al, 2007). However, these studies were uncontrolled, and patient 
selection was wholly at the discretion of the investigators.  A fuller retrospective dataset from the 
same centre, that included patients treated off study protocols, demonstrated inferior results, but on 
multivariate analysis a second transplant was still associated with prolonged PFS and OS (Pineda-
Roman et al, 2008). 
Most randomised trials comparing single with tandem ASCT have shown no benefit in overall 
survival  from tandem stem cell transplantation (Attal et al, 2003; Fermand et al, 2005b; Cavo et al, 
2007; Mai et al, 2016; Sonneveld et al, 2007; reviewed by Kumar et al, 2009). Many of these trials 
utilised non-standard conditioning regimens (e.g. oral busulfan or TBI) which have since been shown 
to be inferior to standard mel200 (Attal et al, 2003; Fermand et al, 2005b; Cavo et al, 2007; 
Sonneveld et al, 2007). However the GMMG-HD2 trial, which used tandem standard mel200 ASCT, 
showed no difference in survival (Mai et al, 2016). The only trial to show a significant benefit for 
both PFS and OS was the IFM-94 study, but the outcomes (in both groups) were poor compared with 
more recent trials using newer agents as part of the treatment protocol (Attal et al, 2003). In a non-
randomized comparison between the Dutch protocol (single transplant) and the German protocol 
(tandem ASCT), the latter was superior for overall survival, but regional variations in demographics 
and treatment could account for this difference (Sonneveld et al, 2013). Subgroup analyses suggest 
there may be a survival advantage from a second ASCT in those patients who fail to achieve a deep 
response to the first ASCT (Attal et al, 2003; Cavo et al, 2007). In the majority of trials, treatment-
related mortality is higher in the tandem ASCT arm, and in addition to this acute risk there may be an 
increased risk of long term complications such as second malignancies and myelodysplastic 
syndrome, although it is not clear that ASCT increases that risk over high dose conventional 
chemotherapy (Govindarajan et al, 1996). The deep responses achieved with proteasome inhibitors 
and immunomodulatory drug-based conditioning regimens, and wider use of consolidation and 
maintenance therapies, have both limited the use of tandem stem cell transplantation.  
Consolidation 
Relapse remains inevitable following ASCT, and consolidation therapy after transplant has been 
investigated as a way of prolonging progression-free survival, by deepening post transplant response. 
Several phase II and phase III studies of post-ASCT consolidation have been performed over the last 
5 years (Table III), but there is not rigorous data to support its efficacy. Only one phase III trial is 
placebo controlled (Mellqvist et al, 2013), and uncontrolled studies are not able to be informative, 
because responses improve over months after ASCT regardless of further treatment. In a phase II 
comparison with historical controls, patients receiving cyclophosphamide, thalidomide and 
dexamethasone consolidation achieved better responses at 12 months (72% ≥VGPR versus 51%) 
(Rabin et al, 2012). In a phase III RCT bortezomib alone improved response and progression free 
survival but with no improvement in overall survival (Mellqvist et al, 2013).  In a phase III trial of 
adding bortezomib to thalidomide and dexamethasone (i.e. VTD vs TD) for both induction and 
consolidation, there was no overall survival benefit, but 3-year progression free survival increased 
from 56% to 68% commensurate with deepening response (Cavo et al, 2010). The consistent finding 
of deeper responses with delayed progression but no effect on overall survival likely reflects more 
effective salvage treatment at relapse for the control group. 
 There are no randomised data on lenalidomide-based consolidation, but in an RCT of lenalidomide 
maintenance, all patients from both arms first received 2 months of lenalidomide consolidation and 
over this period the rate of ≥ VGPR increased from 58% to 69% (Attal et al, 2012). A phase II study 
of lenalidomide, bortezomib and dexamethasone in both induction and consolidation demonstrated 
good responses and impressive survival data with an estimated 77% 3 year progression-free survival 
(Roussel et al, 2014). Results from a phase II study of carfilzomib, lenalidomide and dexamethasone 
for induction, consolidation and maintenance (with lower doses of carfilzomib) showed that 88% of 
patients were MRD-negative after 4 cycles of consolidation, which will hopefully be reflected in 
future improved survival data (Zimmerman et al, 2015).  Survival benefits from consolidation 
strategies following ASCT have yet to be confirmed in randomised studies. 
Maintenance 
Relapse after ASCT is primarily due to residual myeloma cells which continue to survive and 
proliferate, and maintenance therapy aims to control this process, by giving continuous low dose 
therapy until relapse (Table IV). However a concern is that although progression is delayed on 
maintenance, at relapse the disease could be refractory to further treatment and so benefits in overall 
survival would be limited. Such benefits must be balanced against toxicity, quality of life and cost 
effectiveness, given the long duration of maintenance approaches. Earlier maintenance studies did not 
include any consolidation, and the survival plots often diverge early, which suggests that most benefit 
is gained early after transplant. It is unclear if there are advantages to commencing maintenance after 
an effective course of consolidation treatment. 
Interferon alpha had been used as a maintenance agent for many years, but it is uniformly poorly 
tolerated. Used as maintenance therapy after conventional chemotherapy, interferon alpha modestly 
prolonged PFS with no effect on OS (Drayson et al, 1998) but the US Intergroup S9321 trial found 
that it made no difference to progression or survival following ASCT (Barlogie et al, 2006a). A 
therapeutic dose of prednisolone conferred a survival benefit when used after VAD-based 
conventional chemotherapy (Berenson et al, 2002) but glucocorticoids as monotherapy in the post-
ASCT population are redundant now given the improved clinical activity and tolerability observed 
with IMiDs and proteasome inhibitors. In a phase III comparison between dexamethasone and 
interferon maintenance, the dexamethasone group responded very badly to melphalan/dexamethasone 
at relapse, presumably due to selection of resistant clones (Alexanian et al, 2000).  
Thalidomide maintenance has been subjected to a number of phase III trials, conferring a 10% 
increase in 4-year survival rate compared with no maintenance (Attal et al, 2006), and in an RCT 
comparing thalidomide plus prednisolone versus prednisolone alone, overall survival was increased 
by 10% at 3 years (Spencer et al, 2009). A smaller RCT of similar design found a non-significant 
trend towards increased survival in the thalidomide arm (Maiolino et al, 2012). However an RCT of 
thalidomide plus prednisolone versus no maintenance found no overall survival difference, and 
highlighted worse quality of life scores in the maintenance group (Stewart et al, 2013). In all of these 
trials, adverse events of grade 3 or 4 were much more common in the thalidomide arm, and this is 
reflected in a thalidomide discontinuation rate of 30% within a year in the study by Spencer et al. 
In a joint German/Dutch trial comparing induction and maintenance with bortezomib versus 
vincristine-based induction and thalidomide maintenance, there were improved response rates and 
PFS, but overall survival difference barely reached statistical significance (p=0.049) on a multivariate 
analysis (Sonneveld et al, 2012). There was no difference in response during the maintenance phase, 
between the two arms. In a post-hoc analysis, patients with renal impairment gained a significant 
benefit from the bortezomib arm (Scheid et al, 2014).  
Two large RCTs of lenalidomide maintenance against placebo showed an early benefit in progression-
free survival, which in the CALGB study prompted early termination (McCarthy et al, 2012). The 
CALGB trial (n=460) subsequently showed a small OS benefit, but no OS difference was seen in the 
IFM study (n=614). This study gave both arms 2 cycles of lenalidomide consolidation at a higher dose 
before randomisation (Attal et al, 2012) and the Kaplan-Meier overall survival plot of the CALBG 
study diverges early and is parallel thereafter, which suggested that any benefit in overall survival is 
derived from the first few months on lenalidomide. Both studies agreed that there are considerable 
toxicities from lenalidomide, with increased haematological adverse events and secondary cancers 
seen in the lenalidomide groups. 
Combining bortezomib with lenalidomide in maintenance confers a high side effect burden, but in a 
phase II study demonstrated good results in patients with high risk myeloma or plasma cell leukaemia, 
with 93% overall survival at 3 years, and no patients stopped maintenance due to toxicity (Nooka et 
al, 2014). A non-randomised comparison between sequential cohorts receiving bortezomib and 
dexamethasone with either lenalidomide or thalidomide, as maintenance for low risk myeloma found 
no difference in survival or relapse rates (Nair et al, 2010). Maintenance with VRD is yet to be 
studied in a phase III randomised trial. 
New agents 
Histone deacetylase inhibitors (vorinostat and panobinostat) have been explored in phase III trials of 
relapsed/refractory myeloma in combination with bortezomib. Vorinostat demonstrated limited 
activity (Dimopoulos et al, 2013) but panobinostat in combination with bortezomib and 
dexamethasone increased progression free survival with overall survival data yet to show a significant 
difference (San-Miguel et al, 2014). Vorinostat has been combined with lenalidomide for 
maintenance after ASCT in a phase I study, with 14 of the 16 subjects having grade 3 or 4 adverse 
events during maintenance (Sborov et al, 2015), which compares unfavourably with lenalidomide 
monotherapy maintenance trials (McCarthy et al, 2012; Attal et al, 2012). 
Several new monoclonal antibodies, antibody-drug conjugates and small molecules are in phase II and 
III trials for both newly diagnosed and relapsed/refractory myeloma. Adding elotuzumab (targeting 
SLAMF7) to lenalidomide and dexamethasone increased the response rate from 66% to 79% in 
relapsed or refractory patients, and progression-free survival from 14.9 months to 19.4 months in a 
phase III trial (Lonial et al, 2015). A phase I trial of elotuzumab in combination with  bortezomib 
induced responses in 48% of patients with relapsed/refractory myeloma (Jakubowiak et al, 2012). The 
anti-CD38 daratumumab looks promising in phase I/II trials (Plesner et al, 2014; Moreau et al, 2014; 
Lokhorst et al, 2015), and three phase III trials of daratumumab plus various chemotherapy regimens 
are currently recruiting in newly diagnosed and relapsed populations. The antibody-drug conjugates 
lorvotuzumab mertansine (with lenalidomide/dexamethasone, ORR 59%) (Berdeja et al, 2012) and 
indatuximab ravanstine (with lenalidomide/dexamethasone, ORR 78%)  (Kelly et al, 2014); and the 
AKT inhibitor afuresertib (with bortezomib/dexamethasone, ORR 49%)  (Voorhees et al, 2013) 
demonstrate activity in phase I trials in relapsed/refractory patients. Phase I trials of anti-PD1 
monoclonal antibodies in combination with IMiDs (Badros et al, 2015; San Miguel et al, 2015), the 
anti-CD74 conjugate milatuzumab-doxorubicin and an anti-CD200 antibody are currently ongoing in 
relapsed myeloma. 
None of these new agents is currently being investigated as part of an ASCT treatment protocol.  
Monoclonal antibodies are not particularly myelosuppressive: elotuzumab has lower neutropenia rates 
than the control group (Lonial et al, 2015), and although a minority of patients receiving 
daratumumab developed low cell counts this was not dose-dependent (Lokhorst et al, 2015). Given 
this low toxicity they are attractive targeted therapies for use in consolidation and maintenance 
phases, to inhibit residual myeloma clones. 
Immunotherapy and cellular therapy 
The reconstitution of the immune system following ASCT is an opportunity to augment the immune 
response against myeloma. Natural killer cells, components of the innate immune system with the 
potential to kill cancer cells, reconstitute quickly after ASCT, and the number of NK cells at day 30 
correlates with PFS after ASCT (Rueff et al, 2014). Lymphocyte populations recover gradually over a 
year or more, and the early populations are abnormal, with an excess of CD8+ T cells and few CD4+ 
T cells, which have a narrow T-cell receptor repertoire. The lymphodepletion brought on by high dose 
therapy causes levels of cytokines IL-5 and IL-17 to rise, which in turn drive extrathymic proliferation 
of CD4+ T cells. This expansion of T cells in the absence of Treg expansion may facilitate an 
effective anti-myeloma adaptive immune response.   
Maintenance therapy with interferon alpha was the earliest immunomodulatory therapy, augmenting 
the cellular anti-myeloma response and, although modestly effective as maintenance after ASCT, it 
was not adopted due to poor tolerability (Barlogie et al, 2006a). Another approach used ciclosporin in 
a small population of mixed haematological malignancies for one month after ASCT  leading to a 
reaction akin to acute graft-versus-host disease, which was associated with improved disease-free 
survival but no overall survival difference (Marin et al, 2001).  
Vaccine strategies include myeloma-Dendritic Cell (DC) fusion, autologous serum-loaded DCs, 
myeloma-peptide-stimulated T cells, and idiotypic DNA vaccination (fig. 1). A phase I trial of 
autologous DC-myeloma cell fusion cells injected into myeloma patients found these induced 
expansion of myeloma-specific T cells in vivo, and stabilised disease progression in 11 of 16 patients 
(Rosenblatt et al, 2011). A small trial from the Mayo clinic of ex vivo stimulated DCs accompanying 
ASCT found improved survival compared to matched historical controls (Lacy et al, 2009), and a 
small Czech study looking at ex vivo stimulated DCs as monotherapy in pretreated patients found a 
modest improvement in outcomes (Zahradova et al, 2012). Two small trials of myeloma peptide 
vaccines followed by ex vivo T cell expansion and reinfusion showed these to be safe and effective at 
inducing lymphocyte responses (Rapoport et al, 2011; Rapoport et al, 2014) but no effect on clinical 
outcomes could be discerned from these small groups with only the former including a control arm. 
DNA vaccines (variable regions of paraprotein heavy and light chains, fused to tetanus toxin, in an 
expression vector) appear to be safe in phase I trials, though they only elicited an anti-idiotype 
immune response in 4 of 14 subjects (McCann et al, 2015).  These vaccine strategies merit further 
investigation in clinical trials. 
Engineered T cells with chimeric antigen receptors (CAR), which combine the antigen-binding 
fragment of antibodies with the signalling domains of the T cell receptor, have been used with some 
success against advanced leukaemias and lymphomas (Maude et al, 2014; Kochenderfer et al, 2013). 
CAR T cells targeting CD19 have been used as part of ASCT in 10 myeloma patients who were 
heavily pre-treated; 4 have responded to date, with one patient achieving a stringent CR which has 
lasted over 12 months (Garfall et al, 2015). CAR T cells against CD38 can effectively kill myeloma 
cells in vitro (Mihara et al, 2011), and phase I trials are ongoing for these (NCT01886976), and 
chimeric anti-kappa light chain T cells (NCT00881920). Toxicities from CAR T cell therapies include 
an infusional cytokine release syndrome and potential off target effects. In mouse studies, ex vivo 
expanded NK cells can inhibit growth of myeloma tumours (Garg et al, 2012). This concept is 
explored in phase I studies of autologous expanded NK cells (with chemotherapy, but without 
transplantation) in relapsed myeloma patients (NCT01313897; NCT01884688). Haploidentical but 
KIR-mismatched allogeneic NK cells are also being investigated as an adjunct to ASCT (Shi et al, 
2008). 
Trial endpoints 
Overall survival remains the gold standard endpoint for trials in myeloma, but survival rates have 
improved with over a third of newly diagnosed patients living longer than 10 years in the UK (Cancer 
Research UK, 2014), so OS is a late endpoint for trials to report. Complete response rate has 
historically correlated poorly with overall survival (Baldini 1991; Riccardi et al, 2003; Durie et al, 
2004), and clearly does not take account of quality of life aspects, which are affected by increasingly 
prolonged myeloma therapy regimens. In early trials, time to progression did correlate with overall 
survival, but with consolidation treatment this association is no longer seen (Alexanian et al, 2000; 
Attal et al, 2012; Maiolino et al, 2012; Sonneveld et al, 2012; Stewart et al, 2013). PFS2, the time 
from first treatment to second relapse, takes account of tumour resistance induced by the first line of 
treatment, and to date studies have shown it is prolonged in association with PFS (Palumbo et al, 
2014b; Tacchetti et al, 2014), but it has not yet been validated as a surrogate for OS, and still takes 
years of follow up to report mature data. By contrast, recent ASCT trials have shown an association 
between the depth of response and overall survival (Harousseau et al, 2009; Lahuerta et al, 2008) and 
this is particularly the case for prolonged (>3 years) complete response (Barlogie et al, 2008). 
However complete response rate still remains a relatively insensitive surrogate for overall survival, 
and as median survival continues to improve, particularly for transplant-eligible populations, we have 
to adopt earlier endpoints to study the gamut of new agents entering the field. Measuring MRD by 
multi-parameter flow cytometry accurately predicts overall survival in patients who have achieved a 
complete response (Paiva et al, 2012; Rawstron et al, 2015) and represents an opportunity to vastly 
shorten the time required for trials of aggressive treatment to report. 18F-flurodeoxyglucose positron 
emission tomography (PET) CT scanning is also a predictor of PFS and OS, both after induction 
(Bartel et al, 2009) and after ASCT (Zamagni et al, 2015). Its predictive power is independent of CR 
status, but further studies are needed combining MRD measurement and PET CT to determine 
whether both independently provide prognostic information. These trials will still need long term 
follow up to identify late adverse events, the impact on quality of life and hopefully confirm the 
predictive power of these new endpoints.  
Outstanding questions and future trial designs 
We await with interest the final results of several studies testing ASCT against a block of novel agent 
consolidation therapy. Both PFS and OS remain crucial end points, as the latter depends on the ability 
to salvage patients following relapse. Future trials should be randomised and stratified by genetic risk 
to provide clear guidance for treatment decisions. Trials should consider using new end points such as 
MRD negativity (by high throughput flow cytometry or genetic sequencing) and sustained CR rates in 
addition to PFS and OS. A number of key questions  should be addressed in the debate over ASCT as 
standard practice following induction therapy: 
1. Is there a more effective conditioning regimen than mel200? 
2. Does a block of consolidation therapy between ASCT and maintenance therapy improve 
clinical outcomes versus maintenance alone? 
3. Does the addition of a proteasome inhibitor to IMiD-based maintenance improve outcomes? 
4. What role should new monoclonal antibodies and kinase inhibitors play to improve post-
ASCT response? 
5. Are MRD, sustained CR and PET CT-negativity valid surrogate endpoints for overall 
survival? 
Conclusion 
ASCT remains the standard of care for eligible newly diagnosed myeloma patients, despite 
improvements in induction chemotherapy with IMiDs and proteasome inhibitors. Early trials of ASCT 
achieved complete remission lasting >10 years in a small minority of patients (Barlogie et al, 2006 
(III)), and with advances in induction protocols it is likely that with ASCT consolidation this 
proportion will continue to increase. The most promising strategies for improving conditioning 
therapy, on the basis of phase II studies, are the addition of proteasome inhibitors or topoisomerase 
inhibitors, but these require confirmation in randomised trials. Melflufen and radioconjugate drugs 
have yet to be assessed as part of conditioning, but hold theoretical promise. Tandem ASCT upfront 
may improve responses in patients not achieving CR after their first transplant, but it does not offer an 
overall survival benefit over delayed second ASCT at relapse for most patients. We await with 
interest long-term OS data to see if there is a benefit from lenalidomide maintenance.  Treatment 
following ASCT, with both an IMiD and a proteasome inhibitor in combination has achieved 
impressive results in phase II studies, but has not yet been systematically tested in a phase III study. 
Several monoclonal antibodies and kinase inhibitors are promising in early clinical trials and, 
although these targeted drugs are unlikely to replace ASCT, they may find a role in post-ASCT 
consolidation. Experimental therapies to augment cellular immune responses to myeloma have 
demonstrated biological activity in patients refractory to other lines of treatment, and despite high 
potential toxicity they merit investigation in the post-ASCT period, when patients are lymphocyte-
deplete and the burden of disease is low. These new therapeutic strategies could substantially increase 
the proportion of patients achieving long-term disease control after ASCT.  At the same time clinical 
trials need to report more rapidly and hopefully, if MRD continues to robustly translate into survival 
in reported studies, then the adoption in clinical trials of MRD detection as a key end point will 
greatly facilitate this. 
Study Treatment regimen Number of 
patients 
Treatment-
related 
mortality 
(%) 
Overall 
response 
rate (%) 
Median 
progression-
free survival 
(months) 
Median 
overall 
survival 
(months) 
Alkylating agents       
 GEM2000 
Lahuerta et al. (2010) 
2 sequential single arms 
 
Oral busulfan 12mg/kg plus melphalan 140mg/m2 225 8.4 91 41  79  
 Melphalan 200mg/m2 542 3.5 91 31  71  
 
Blanes et al. (2013) 
Matched control study 
Busulfan 9.6mg/kg plus melphalan 140mg/m2 51 4 90 33  65.5  
 
Melphalan 200mg/m2 102 2 91 24  63  
 Desikan et al. (2000) 
Three-way matched control study (conditioning 
for the second of two tandem ASCTs) 
Cylophosphamide 120mg/kg plus melphalan 200mg/m2 19 0  27 39 
 TBI 1125cGy plus melphalan 140mg/m2 24 8  15 25  
 Melphalan 200mg/m2 43 0  61 76  
 
Fenk et al. (2005)* 
RCT 
Idarubicin 42mg/m2, melphalan 200mg/m2 and 
cyclophosphamide 120mg/kg 26 20 85 20 46  
 Melphalan 200mg/m2 30 0 83 16  66  
 
Knop et al. (2007)* 
RCT 
Total marrow irradiation 9Gy, oral busulfan 12mg/kg 
and cyclophosphamide 120mg/kg 100   38  
 Melphalan 200mg/m2 (x2 ASCTs) 98   35  
 Donato et al. (2004) 
Uncontrolled phase I; mixed patient population 
Cyclophosphamide 3g/m2, melphalan 140mg/m2 and 
topotecan 17.5mg/m2 18 0 89   
 Kazmi et al. (2011) 
Uncontrolled phase II; mixed patient population 
Cyclophosphamide 3g/m2, melphalan 140mg/m2 and 
topotecan 17.5mg/m2 60 0 85 18.5 4YS 66% 
 Comenzo et al. (2006) 
Uncontrolled phase I/II Carmustine 300mg/m
2 plus melphalan 200mg/m2 49 2 88 28  56  
 Chen et al. (2012) Carmustine 15mg/kg plus melphalan 200mg/m2 118 0 96 34  61  
 Mark et al. (2013) Melphalan 200mg/m
2 plus bendamustine escalating up 
to 225mg/m2 25 0 100   
Proteasome inhibitors       
 
Roussel et al. (2010) 
Uncontrolled; matched comparison 
Bortezomib 4mg/m2 plus melphalan 200mg/m2 54 0 94   
 Melphalan 200mg/m2 115  97   
 
Huang et al. (2012) 
2 arms stratified by tolerance of bortezomib 
Bortezomib 4mg/m2 plus melphalan 200mg/m2 10 0 100 20   
 Melphalan 200mg/m2 11 0 100 22   
 Miyamoto et al. (2013) 
Uncontrolled; matched comparison 
Bortezomib 1.3 or 2.6mg/m2 plus melphalan 200mg/m2 17 0 100   
 Melphalan 200mg/m2 17 0 100   
 Nishihori et al. (2012) 
Uncontrolled study in primary refractory 
population 
Tandem ASCTs with melphalan 200mg/m2 plus 
bortezomib 0.7-1.3mg/m2 25 0 84 15  40  
Topoisomerase inhibitors       
 Kazmi et al. (2011) 
Uncontrolled study (upfront and refractory) 
Topotecan 17.5mg/m2, melphalan 140mg/m2 and 
cyclophosphamide 3g/m2 60 0 85 18.5   
 Ballestrero et al. (2002) 
Uncontrolled study Mitoxantrone 60mg/m
2 plus melphalan 180mg/m2 20 0 90 26  45  
 Beaven et al. (2011) 
Uncontrolled study (upfront and refractory) Mitoxantrone 60mg/m
2 plus melphalan 180mg/m2 35 3  22 68  
Other agents       
 
Qazilbash et al. (2008)* 
Phase II RCT 
Melphalan 200mg/m2, ascorbic acid 1g, plus arsenic 
trioxide 1.75mg/kg 15 0 86 
25   Melphalan 200mg/m2, ascorbic acid 1g plus arsenic 
trioxide 1.05mg/kg 17 0 70 
 Melphalan 200mg/m2 plus ascorbic acid 1g 16 0 87 
* RCT, randomised controlled trial. TBI, total body irradiation. 4YS, 4 year survival 
 
Table I. Trials of ASCT conditioning regimens since mel200 was established as the standard of care 
Study Treatment regimen Number 
of 
patients 
Treatment-
related 
mortality 
(%) 
Response Median 
progression-
free survival 
(months) 
Median 
overall 
survival 
(months) 
TT1 
Barlogie et al. (2006c) 
3x VAD, cyclophosphamide 6g/m2, EDAP, 2x ASCT with mel200 (or mel140 + 8.5Gy 
TBI), interferon maintenance  231 5 40%≥VGPR 31 68  
TT3 
Barlogie et al. (2007) 
2xVTD-PACE, 2x ASCT with mel200, 2xVTD-PACE, VTD for 1 year then TD for 2 
years 303 5 56%≥VGPR 65% 5YPFS 
74% 
5YS 
IFM-94* 
Attal et al. (2003) 
RCT 
3-4xVAD, 1x ASCT with mel140, 1x ASCT with mel140+8GyTBI, interferon 
maintenance 200 6 50%≥VGPR 36  58  
3-4xVAD, 1x ASCT with mel140+8GyTBI, interferon maintenance 199 4 42%≥VGPR 29  48  
MAG95* 
Fermand et al. (2005) 
RCT 
High dose steroid and cyclophosphamide, 1x ASCT with Mel140, 1x ASCT with high 
dose chemotherapy + TBI 12Gy 114 7 38%≥VGPR 34  75  
High dose steroid and cyclophosphamide, 3-4x VAD, 1x ASCT with high dose 
chemotherapy + TBI 12Gy 113 12 37%≥VGPR 31 57  
Bologna 96* 
Cavo et al. (2007) 
RCT 
4x VAD, cyclophosphamide 7g/m2, 1x ASCT with mel200, 1x ASCT mel120 + busulfan 
12mg/kg, interferon maintenance 158 6 33%≥nCR 42  71  
4x VAD, cyclophosphamide 7g/m2, 1x ASCT mel200, interferon maintenance 163 6 47%≥nCR 24  65  
GMMG-HD2* 
Mai et al. (2016) 
RCT 
Up to 6x VAD or VID, cyclophosphamide 4g/m2, 2x ASCT with mel200, interferon 
maintenance 181 5 19% CR 29  75  
Up to 6x VAD or VID, cyclophosphamide 4g/m2, 1x ASCT with mel200, interferon 
maintenance 177 2 16% CR 25  73  
HOVON 24* 
Sonneveld et al. (2007) 
RCT 
3-4x VAD, cyclophosphamide 4g/m2, 2x mel70 (without ASCT), ASCT with 
cyclophosphamide 120mg/kg + TBI 9Gy, interferon maintenance 155 10 32% CR 27  50  
3-4x VAD, cyclophosphamide 4g/m2, 2x mel70 (without ASCT), interferon maintenance 148 4 13% CR 24  55  
VAD, vincristine/doxorubicin/dexamethasone. EDAP, etoposide/dexamethasone/cytarabine/cisplatin. VTD-PACE, bortezomib/thalidomide/dexamethasone with 
cisplatin/doxorubicin/cyclophosphamide/etoposide. TD, thalidomide/dexamethasone. VID, vincristine, idarubicin, dexamethasone. nCR, near-complete response (paraprotein only detectable 
with immunofixation) 
 
Table II. Trials of tandem ASCT following induction 
Study Treatment regimen Number of 
patients 
Proportion with 
adverse events of 
grade 3/4 (%) 
Proportion 
attaining 
≥VGPR (%) 
Median 
progression-free 
survival (months) 
Median overall 
survival 
(months) 
Rabin et al. (2012) 
Phase II after ASCT 
3-6 cycles of CTD consolidation 45 40 72 26 (from consolidation) 
NR 
No consolidation 40  51 21  71 months 
Mellqvist et al. (2013)* 
RCT after ASCT 
Bortezomib 1.3mg/m2 (20 doses) 187 11 71 27 (from consolidation) 
79% 3YS 
No consolidation 183 2 57 20  82% 3YS 
Cavo et al. (2010)* 
RCT 
3x VTD induction, tandem ASCT then 2x VTD 
consolidation 236 56 89 
68% 3YS (from 
induction) 
86% 3YS 
3x TD induction, tandem ASCT then 2x TD 
consolidation 238 33 74 56% 3YS 
84% 3YS 
Ladetto et al. (2010) 
Phase II 
Recruiting ≥VGPR after ASCT 
4xVTD consolidation 39 54 100% (at recruitment) 
60 
(frominduction) 
89% 3YS 
Leleu et al. (2013) 
Retrospective cohort study 
3x VTD, ASCT, then 2x VTD consolidation 121  83 62% 4YS 91% 4YS (estimated) 
3x VTD, ASCT, no consolidation 96  64  29% 4YS 84% 4YS (estimated) 
Attal et al. (2012) 
(Pre-maintenance analysis) 
After ASCT, 2x lenalidomide consolidation (thereafter 
randomised to maintenance or nil) 577  
69% (after 
consolidation) 
32% 4YS (from 
consolidation) 
74% 4YS 
Roussel et al. (2014) 
Phase II 
3x RVD induction, ASCT with mel200, then 2x RVD 
consolidation, then 1 year lenalidomide maintenance 31 74 84 
77% 3YS (from 
induction) 
100% 3YS  
CTD, cylophosphamide/thalidomide/dexamethasone. VTD, bortezomib/thalidomide/dexamethasone. TD, thalidomide/dexamethasone. RVD, lenalidomide/bortezomib/dexamethasone. 
3YS/4YS, 3/4 year survival respectively. 
Table III. Consolidation trials post ASCT in myeloma 
 
Study Treatment regimen Number of 
patients 
Adverse events of 
grade 3/4 (% of 
patients, or 
absolute number) 
Proportion 
attaining 
≥VGPR (%) 
Median 
progression-
free survival 
(months) 
Median overall 
survival (months) 
S9321* 
Barlogie et al.(2006) 
RCT 
After ASCT or conventional therapy, interferon 
maintenance 121   23  69  
After ASCT or conventional therapy, no maintenance 121   18  62  
Attal et al.(2006)* 
RCT 
After ASCT, pamidronate 90mg plus thalidomide 
400mg maintenance 201 177 events 67 51% 3YS 87% 4YS 
After ASCT, pamidronate maintenance 196 65 events 57 39% 3YS 74% 4YS 
After ASCT, no maintenance 200 40 events 55 38% 3YS 77% 4YS 
Stewart et al.(2013)* 
RCT 
After ASCT, thalidomide 200mg and prednisolone 
maintenance 165 140 events  28  68% 4YS 
After ASCT, no maintenance 163 39 events  17  60% 4YS 
Spencer et al.(2009)* 
RCT following ASCT 
Thalidomide 100-200mg for 1 year and indefinite 
prednisolone maintenance 114 51 events 65 
31  (from 
maintenance) 
86% 3YS (from 
maintenance) 
Indefinite prednisolone maintenance 129 32 events 44 18   75% 3YS 
Maiolino et al.(2012)* 
RCT 
After ASCT, dexamethasone plus thalidomide 200mg 
maintenance for 1 year 56 20 events 50 36  85% 2YS 
After ASCT, dexamethasone maintenance for 1 year 52 4 events 48 19  70% 2YS 
Sonneveld et al.(2012)* 
RCT 
PAD induction, ASCT, bortezomib 1.3mg/m2 
maintenance for 2 years 413 48%  76 35  61% 5YS 
VAD induction, ASCT, thalidomide 50mg 
maintenance for 2 years 414 46% 
56 
 
 
28  55% 5YS 
Attal et al.(2012)* 
RCT 
After ASCT, 2 cycles lenalidomide consolidation 
(25mg), then lenalidomide 10-15mg od until relapse 307 74% 84 41  73% 4YS 
After ASCT, 2 cycles lenalidomide consolidation 
(25mg), then no maintenance 307 43% 76 23  75% 4YS 
McCarthy et al.(2012)* 
RCT 
After ASCT, Lenalidomide 10-15mg maintenance 231 60%  46  88% 3YS 
After ASCT, Placebo  229 30%  27  80% 3YS 
Palumbo et al.(2014)* 
2x2 RCT 
After ASCT or MPR, lenalidomide 10mg 
maintenance 126 53 events  42  88% 3YS 
After ASCT or MPR, no maintenance 125 7 events  22  80% 3YS 
Gay et al. (2015)* 
2x2 RCT 
After ASCT or CRD, lenalidomide 10mg plus 
prednisolone maintenance 194 20%  
38 (from 
maintenance) 83% 3YS  
After ASCT or CRD, lenalidomide 10mg 
maintenance 198 20%  29 88% 3YS 
Nair et al.(2010) 
Comparison between TT3 
and TT6 cohorts 
After 2x ASCT, 3 years of VRD 177  61% CR 80% 2YS 85% 2YS 
After 2x ASCT, 1 year of bortezomib and 3 years of 
thalidomide plus dexamethasone 303  59% CR 83% 2YS 87% 2YS 
Nooka et al.(2014) 
Phase II study in high risk 
disease 
After ASCT,  3 years of RVD 45  96 32  93% 3YS 
PAD, bortezomib, doxorubicin and dexamethasone; MPR, melphalan, prednisolone and lenalidomide; CRD, cyclophosphamide/lenalidomide/dexamethasone. 
 
Table IV. Maintenance therapy trials after ASCT 
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